TO review the literature that compares Zolpidem with triazolam, with an emphasis on efficacy and safety in humans.
DATA SOURCES:
Information was retrieved from a MEDLINE search (1983–1996) of the English-language literature using the terms triazolam and zolpidem.
STUDY SELECTION:
Reports of clinical trials comparing the safety and efficacy of zolpidem and triazolam were included in this review.
DATA EXTRACTION:
Data were evaluated according to study design, efficacy, and adverse effects. Pertinent information was selected and the data synthesized into a review format.
DATA SYNTHESIS:
Zolpidem and triazolam have similar pharmacokinetic and pharmacodynamic effects in humans. Clinical trials have shown that usually recommended, equipotent dosages of zolpidem and triazolam do not differ with respect to pharmacokinetics, efficacy, tolerability, residual effects, memory impairment, rebound insomnia, abuse potential, or other adverse effects.
CONCLUSIONS:
Zolpidem offers no distinct therapeutic advantage over triazolam for the treatment of insomnia.
WalshJKEngelhardtCL. Trends in the pharmacologic treatment of insomnia. J Clin Psychiatry1992,53:12 (suppl):10–7.
2.
DopheideJA. Sleep disorders. In: YoungLYKoda-KimbleMA, eds. Applied therapeutics: The clinical use of drugs. Vancouver WA: Applied Therapeutics Inc., 1995: 74.
3.
Top 200 drugs of 1995. Pharm Times1996: April:27–36.
4.
KlettCJ. Review of triazolam data. J Clin Psychiatry1992: 53:12(suppl):61–7.
5.
BalterMBUhlenhuthEH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry1992: 53:12(suppl):34–9.
SalvaPCostaJ. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Clin Pharmacokinet1995: 29: 142–53.
8.
MetzlerCMRoyerMEVeldkampWLinetOI. Bioavailability and pharmacokinetics of orally administered triazolam in normal subjects (abstract). Clin Pharmacol Ther1977; 21: 111–2.
9.
Product information.Halcion (triazolam). Kalamazoo, MI: The Upjohn Company, July 1993.
10.
BianchettiGDubrucCThiercelinJFBercoffEBouchetJLEmeriauJPClinical pharmacokinetics of zolpidem in various physiological and pathological conditions. In: SauvanetJPLangerSZMorselliPL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 155–63.
11.
PichardLGilletGBonfilsCDomergueJThenotJPMaurelP. Oxidative metabolism of zolpidem by human liver cytochrome. Drug Metab Dispos1995; 23: 1253–62.
12.
LangerSZArbillaSScattonBNiddamRDuboisA. Receptors involved in the mechanism of action of zolpidem. In: SauvanetJPLangerSZMorselliPL, eds. Imidazopyridines in sleep disorders.New York: Raven Press, 1988: 55–70.
13.
ZivkovicBPerraultGMorelESangerDJ. Comparative pharmacology of zolpidem and other hypnotics and sleep inducers. In: SauvanetJPLangerSZMorselliPL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 97–109.
14.
SangerDJJolyDZivkovicB. The behavioral pharmacology of zolpidem: Comparisons with other compounds acting at the benzodiazepine receptor. In: SauvanetJPLangerSZMorselliPL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 111–21.
15.
RosenbergJAhlstromF. Randomized, double-blind trial of Zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice. Scand J Prim Health Care1994; 12 (2):88–92.
16.
PagotRCramerPL'héritierCCoquelinJPAttaliP. Comparison of the efficacy and tolerability of Zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients. Curr Ther Res1993; 53: 88–97.
17.
RogerMAttaliPCoquelinJP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther1993; 15: 127–36.
18.
LouvelECramerPFerreriMPagotRRegnierFHeritierCLZolpidem and triazolam: Long-term multicenter studies (1–3 months) in psychiatric and general practice patients. In: SauvanetJPLangerSZMorselliPL, eds. Imidazopyridines in sleep disorders.New York: Raven Press, 1988: 327–37.
19.
JonasJMColemanBSSheridaAQKalinskeRW. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiatry1992; 53:12(suppl): 19–31.
20.
GillinCJByerleyWF. The diagnosis and management of insomnia. N Engl J Med1990; 322: 239–47.
21.
WheatleyD. Prescribing short-acting hypnosedatives — Current recommendations from a safety perspective. Drug Saf1992; 7: 106–15.
22.
BartholiniG. Growing aspects of hypnotic drugs. In: SauvanetJPLangerSZMorselliPL, eds. Imidazopyridines in sleep disorders.New York: Raven Press, 1988: 1–9.
23.
BondA. The risks of taking benzodiazepines. In: HallstromC, ed. Benzodiazepine dependence. Oxford: Oxford University Press, 1993: 35–45.
24.
MendelsonWB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry1992; 53:12(suppl):4–7.
25.
GreenblattDJHarmatzJSShaderRI. Does Zolpidem have unique clinical properties? A pharmacodynamic comparison with triazolam and placebo (abstract). Clin Pharmacol Ther1996; 59: 178.
26.
WesenstenNJBalkinTJBelenkyGL. Effects of daytime administration of zolpidem and triazolam on performance. Aviat Space Environ Med1996; 67 (2):115–20.
27.
WesenstenNJBalkinTJBelenkyGL. Effects of daytime administration of Zolpidem versus triazolam on memory. Eur J Clin Pharmacol1995; 48: 115–22.
28.
BerlinIWarotDHerguetaTMolinierPBagotCPuechAJ. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol1993; 13: 100–6.
29.
MorselliPLLarribaudJGuilletPThiercelinJFBartheletGGrilliatJPDaytime residual effects of zolpidem: A review of available data. In: SauvanetJPLangerSZMorselliPL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 183–91.
30.
BergougnanLHippiusHRutherELundRKeilingerMSpeieriAStudy on Polysomnographic and daytime residual effects after single doses of Zolpidem, triazolam, lormetazepam, and placebo in healthy volunteers (abstract). J Sleep Res1992; L (suppl):21.
31.
LundRRütherEWoberWHippiusH. Effects of zolpidem (10 and 20 mg), lormetazepam, triazolam, and placebo on night sleep and residual effects during the day. In: SauvanetJPLangerSZMorselliPL, eds. Imidazopyridines in sleep disorders.New York: Raven Press, 1988: 193–203.
32.
WesenstenNJBalkinTJDavisHQBelenkyGL. Reversal of triazolam- and zolpidem-induced memory impairment by flumazenil. Psychopharmacology1995; 121: 242–9.
33.
LaderM. Historical development of the concept of tranquillizer dependence. In: HallstromC, ed. Benzodiazepine dependence. Oxford: Oxford University Press, 1993: 46–57.
34.
MontiJMAttaliPMontiDZipfelAde la GiclaisBMorselliPL. Zolpidem and rebound insomnia — A double-blind, controlled Polysomnographic study in chronic insomniac patients. Pharmacopsychiatry1994; 27: 166–75.
35.
MontiJMMontiDAttaliP. Comparative hypnotic and withdrawal effects of zolpidem, triazolam, and placebo in insomniac patients (abstract). J Sleep Res1992; L (suppl):153.
36.
HiggittAFonagyP. Benzodiazepine dependence syndromes and syndromes of withdrawal. In: HallstromC, ed. Benzodiazepine dependence.Oxford: Oxford University Press, 1993: 58–70.
37.
EvansSMFunderburkFRGriffithsRR. Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther1990; 255: 1246–55.
38.
CavallaroRRegazzettiMGCovelliG. Tolerance and withdrawal with zolpidem. Lancet1993; 342: 374–5.
39.
AbernethyDRGreenblattDJDivollMMoschittoLJHarmatzJSShaderRI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology1983; 80: 275–8.
40.
StoehrGPKrobothPDJuhlRPWenderDBPhillipsJPSmithRB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther1984; 36: 683–90.
41.
VarheAOlkkolaKTNeuvonenPJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther1996; 59: 369–75.
42.
HukkinenSKVarheAOlkkolaKTNeuvonenPJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther1995; 58: 127–31.
43.
PhillipsJPAntalEJSmithRB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol1986; 6: 297–9.
44.
WrightCELasher-SissonTASwansonCN. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy1992; 12: 103–6.
45.
GreenblattDJvon MoltkeLLHarmatzLSHarrelLMTobiasSShaderRIInteraction of triazolam and ketoconazole (letter). Lancet1995; 345: 191.
46.
VarheAOlkkolaKTNeuvonenPJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther1994; 56: 601–7.
47.
OchsHRGreenblattDJKnuchelM. Differential effects of isoniazid on triazolam metabolism and oxazepam conjugation. Br J Clin Pharmacol1983; 16: 743–6.
48.
GreeneDSDockensRCSalazarDEBarbaiyaRH. Coadministration of nefazodone and benzodiazepines I: Pharmacokinetic assessment (abstract). Clin Pharmacol Ther1994; 55: 141.
49.
HulhovenRDesagerJPHarvengtCHermannPGuilletPTheircelinJF. Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Res1988; 8: 471–6.
50.
DesagerJPHulhovenRHarvengtCHermannPGuilletPThiercelinJF. Possible interactions between Zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology1988; 96: 63–6.
51.
Halcion 8500-patient post-marketing study final technical reports being prepared for submission to the FDA. F-D-C Rep1996;June 10:5.
52.
Halcion safety, efficacy data should be reviewed anew by FDA advisory cmte; Upjohn criminal investigation should go to justice — FDA task force. F-D-C Rep1996;June 3:5.
